中药逆转EGFR-TKIs治疗NSCLC获得性耐药的分子机制及研究进展  

Mechanisms and Research Progress of Reversal EGFR-TKIs Acquired Resistance in NSCLC with Traditional Chinese Medicine

作　　者：李光达 马云飞[1] 程培育[1] 于明薇[1] 王笑民[1] LI Guang-da;MA Yun-fei;CHENG Pei-yu;YU Ming-wei;WANG Xiao-min(Beijing Hospital of Traditional Chinese Medicine Affiliated toCapital Medical University,Beijing 100010,China)

机构地区：[1]首都医科大学附属北京中医医院,北京100010

出　　处：《中医药导报》2020年第1期114-118,共5页Guiding Journal of Traditional Chinese Medicine and Pharmacy

基　　金：北京中医医院院级课题暨两院合作课题(YJ-201803);国家自然科学基金(81473643,81774039);北京市科技计划(Z161100000116061);北京市医院管理局“登峰”人才培养计划(DFL20150901)。

摘　　要：总结归纳近10年中药逆转表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptortyrosine kinase inhibitor,EGFR-TKI)治疗非小细胞肺癌(NSCLC)获得性耐药的分子机制及研究进展,以期为中药逆转EGFR-TKIs获得性耐药提供科学依据,并为中药在此领域中的应用提供新的思路与方法。中医药主要通过抑制表面生长因子受体(epidermal growth factor receptor,EGFR)旁路或下游通路、逆转上皮间质转化(EMT)两个方面逆转其耐药。This article summarizes the literatures in the past 10 years,in order to provide a scientific basis for reversing the acquired resistance of epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI)by different Chinese Medicines in treating non-small cell lung cancer(NSCLC),and provides new ideas and methods for the application of Chinese Medicine in this field.Traditional Chinese Medicine has shown certain advantages in this respect,mainly by inhibiting the epidermal growth factor receptor(EGFR)bypass or downstream pathway and reversing the epithelial mesenchymal transition(EMT)to reverse the drug resistance.

关 键 词：非小细胞肺癌 中医药 表皮生长因子受体酪氨酸激酶抑制剂 耐药 机制 

分 类 号：R273[医药卫生—中西医结合]